Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Chlamydia Trachomatis Infection Doubles the Risk for Ovarian Cancer

TON - May 2018, Vol 11, No 2 - Ovarian Cancer
Phoebe Starr

Chicago, IL—Chlamydia trachomatis (chlamydia) infection was shown to increase the risk for developing ovarian cancer by approximately 2-fold in 2 independent studies presented at the 2018 American Association for Cancer Research Annual Meeting. In each of the studies, women who had antibodies against pGP3, a protein that is a validated marker of active or previous chlamydia infection, had twice the risk for being diagnosed with ovarian cancer compared with matched controls. Interestingly, no association was observed between antibodies related to other infections and ovarian cancer in either study.

Chlamydia trachomatis Infection Doubles the Risk for Ovarian Cancer

“The fact that there were no associations with antibodies against other infectious agents really supports the specificity of the association of chlamydia infection with ovarian cancer,” said lead investigator Britton Trabert, PhD, MS, Earl Stadtman Investigator, Division of Cancer Epidemiology and Genetics, Metabolic Epidemiology Branch, National Cancer Institute, Bethesda, MD.

She pointed out that pelvic inflammatory disease (PID) is associated with a doubling of the risk for ovarian cancer, and chlamydia infection is the leading cause of PID.

The studies included a Polish population-based case-control study of 278 women diagnosed with ovarian cancer between 2000 and 2003 and 556 matched controls, and the National Cancer Institute–sponsored Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial, a nested case-control prospective trial with blood drawn prior to diagnosis, that included 160 women who developed ovarian cancer during follow-up and 159 matched controls.

at a glance

    
  • Investigators evaluated 2 independent study populations to examine the relationship between chlamydia infection and the risk for ovarian cancer
  • 
  • Both studies showed that women who had antibodies indicating current or previous chlamydia infection had twice the risk of being diagnosed with ovarian cancer than matched control subjects
  • 
  • The risk for ovarian cancer was not associated with antibodies related to other infections

Risk Factors

Dr Trabert and colleagues measured serologic markers of sexually and nonsexually transmitted infections, including chlamydia, human papilloma virus, herpes simplex virus, hepatitis B, and hepatitis C. The antibody to chlamydia, pGP3, was the only one that was significantly associated with ovarian cancer.

Using the traditional laboratory cut-off point for pGP3 indicative of previous chlamydia infection, the odds ratio for developing ovarian cancer was 1.63 in the Polish study and 1.43 in the PLCO trial. Using a more stringent cut-off point for pGP3, the odds ratios were 2.0 and 2.25, respectively.

“This study suggests that the risk for ovarian cancer could potentially be reduced through screening and treatment of chlamydia infection,” Dr Trabert stated. She said that this study does not answer the question of whether treatment of chlamydia infection prevents ovarian cancer, and that her research team is planning a larger study to confirm these findings and to determine whether chlamydia infection has a stronger association with specific subtypes of ovarian cancer.

“We do need to evaluate whether treatment of PID and chlamydia is preventive,” Dr Trabert said.

A limitation of this study is that the multiplex platform used to test for antibodies was not able to provide reliable results about antibodies to Neisseria gonorrhoeae, another established cause of PID.

American Association for Cancer Research Program Chair Elaine R. Mardis, PhD, Professor and Co-Executive Director, Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, OH, noted that ovarian cancer is typically silent until it is more advanced and, therefore, is associated with a poor prognosis.

“This study is notable for being an international collaboration between the Polish study and the PLCO to provide tissue samples, and it suggests that we can go a long way toward improving detection of ovarian cancer by routine screening for PID and chlamydia,” Dr Mardis said.

Related Items
5 mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Breast Cancer
Weight-Loss Intervention in Women with Breast Cancer Works Only with Adherence
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Breast Cancer
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Immunotherapy
Paradigm Shift: Radiation a New Standard in Prostate Cancer with Low Metastatic Burden
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Prostate Cancer
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Leukemia
First-Line Olaparib a New Standard in Women with Newly Diagnosed, BRCA-Positive Advanced Ovarian Cancer?
Phoebe Starr
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Ovarian Cancer
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer, Immunotherapy
First-Line Olaparib a New Standard in Women with Newly Diagnosed, BRCA-Positive Advanced Ovarian Cancer?
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Ovarian Cancer
Nivolumab plus Ipilimumab Combo Controls Brain Metastases in Patients with Melanoma
Phoebe Starr
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Melanoma
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Emerging Therapies
Last modified: June 13, 2018